Proterguride

Proterguride
Clinical data
Other names	VUFB-13416; VUFB13416; ZK-39437; ZK39437; 6-Propylterguride; 6-Propyl-9,10-dihydrolisuride; N,N-Diethyl-N'-(6-propylergolin-8α-yl)urea
Drug class	Dopamine agonist; Prolactin inhibitor; Antiparkinsonian agent
ATC code	None;
Identifiers
	IUPAC name 3-[(6aR,9S,10aR)-7-propyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinolin-9-yl]-1,1-diethylurea;
CAS Number	77650-95-4;
PubChem CID	71999;
ChemSpider	64999;
UNII	10661OD4VE;
ChEMBL	ChEMBL2106986;
CompTox Dashboard (EPA)	DTXSID70228299 ;
Chemical and physical data
Formula	C22H32N4O
Molar mass	368.525 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCN1C[C@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)NC(=O)N(CC)CC;
	InChI InChI=1S/C22H32N4O/c1-4-10-26-14-16(24-22(27)25(5-2)6-3)12-18-17-8-7-9-19-21(17)15(13-23-19)11-20(18)26/h7-9,13,16,18,20,23H,4-6,10-12,14H2,1-3H3,(H,24,27)/t16-,18+,20+/m0/s1; Key:FCRJELOYDVBTGW-ILZDJORESA-N;

Proterguride (INNTooltip International Nonproprietary Name; developmental code names VUFB-13416, ZK-39437), also known as 6-propylterguride or 6-propyl-9,10-dihydrolisuride, is a dopamine agonist of the ergoline family described as a prolactin inhibitor and antiparkinsonian agent which was never marketed.^[1]^[2]^[3]^[4]^[5] It is closely structurally related to certain other ergolines like terguride and lisuride.^[1]^[4] Besides dopamine receptors, the drug also interacts with serotonin, adrenergic, and histamine receptors.^[5] Proterguride was first described in the literature by at least 1981.^[1]